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Background: Treatment resistant hypertension (TRH) is defined by blood pressure (BP) uncontrolled on ≥3 or controlled on ≥4 BP medications 
including a diuretic at optimal doses. The prevalence of TRH is uncertain.
methods: Electronic record data were analyzed from >200 OQUIN practices in the Southeast US. From 2007-2010, 468,877 hypertensives 
were included. Optimal BP medication dose was defined as ≥50% of maximum recommended hypertension (HTN) dose. BP <140/<90 = control. 
Multivariable logistic regression was used to assess variables independently associated with ‘optimal therapy’ in uncontrolled TRH and control in all 
TRH.
results: 147,635 patients (31.5%) had uncontrolled HTN with 30.3% uncontrolled on ≥3 prescribed BP meds (apparent (a)TRH); 28.7% of aTRH 
patients had Stage 2 HTN. In controlled TRH, 12.3% were prescribed ≥4 BP meds. In uncontrolled aTRH, 49.7% were prescribed ‘optimal’ therapy. 
Factors associated with optimal therapy in uncontrolled TRH included black race (Odds Ratio 1.40 [95% CI 1.32-1.49]), chronic kidney disease 
(1.31 [1.25-1.38] ) diabetes (1.30 [1.24-1.37), and CHD risk equivalent (1.29 [1.14-1.46]). In all TRH patients, factors linked with BP control were 
black race (0.66 [0.63-0.69]), cardiovascular disease (1.40 [1.35-1.45]), prescription of single-pill BP med combinations (1.31 [1.26-1.36]) and 
statins (1.28 [1.22-1.33]). P<0.001 all odds ratios.
conclusions: About 30% of uncontrolled HTN in OQUIN have aTRH with
only half prescribed ‘optimal’ therapy. Optimal therapy is more often prescribed when CVD risk is higher. Black TRH patients are more likely to have 
optimal therapy prescribed but less likely to attain BP control. After accounting for pseudoresistance (reportedly 30%-50%) and suboptimal regimens 
(~50% current report), the uncontrolled TRH population remains large, disproportionately minority, at high CVD risk, and could benefit from effective 
strategies to improve BP control, which may include prescribing of single-pill antihypertensive medication combinations and statins.
